Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00964977 | Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. | completed | Phase 3 | 209 | Johannes Gutenberg University MainzOTHER | 3 | Feb 25, 2022 | clinicaltrials |
| NCT05218395 | Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer | unknown | — | 900 | Qianfoshan HospitalOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04787328 | A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT02562599 | Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin | completed | Phase 2 | 60 | Hubei Cancer HospitalOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT04320901 | Energy Device Study in Transoral Endoscopic Thyroidectomy | unknown | N/A | 40 | Inha University HospitalOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT05247476 | Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients. | unknown | Phase 4 | 50 | Zhongshan Hospital Xiamen UniversityOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT00370890 | A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy | completed | Phase 3 | 104 | Chinese University of Hong KongOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02237924 | Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma | completed | Phase 2 | 120 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02605967 | Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 122 | Novartis PharmaceuticalsINDUSTRY | 7 | Feb 10, 2022 | clinicaltrials |
| NCT02688608 | Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer | completed | Phase 2 | 6 | Saad A KhanOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT03569436 | Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread | completed | — | 262 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT03647657 | 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer | completed | Early Phase 1 | 8 | University Hospital, Basel, SwitzerlandOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05232552 | Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 37 | Zhejiang Cancer HospitalOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT03397238 | Myeloid Cell Reprogramming in Thyroid Carcinoma | completed | — | 41 | Radboud University Medical CenterOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT05146050 | Olfactory Change After Chemo-radiotherapy for Nasopharyngeal Carcinoma | unknown | — | 107 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT05228093 | A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis | unknown | N/A | 216 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04952493 | Anlotinib or Penpulimab in Combination With RAI for DTC | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT03269344 | Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer | completed | Phase 3 | 65 | Henry Ford Health SystemOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02731352 | Study of Apatinib in Patients With Differentiated Thyroid Cancer | completed | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT04995120 | Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma(INSIGHT) | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT05191927 | A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma | completed | — | 1,200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05183724 | Ovarian Function of Nasopharyngeal Carcinoma Women Survivors | unknown | — | 602 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02878044 | Shared Decision Making in Patients With Thyroid Nodules | completed | N/A | 21 | Mayo ClinicOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT05177237 | Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma | unknown | Phase 2 | 30 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT02714920 | DNA Repair Enzyme Signature in Head and Neck Cancer (CHEMRAD)(CHEMRAD) | completed | N/A | 38 | Hospices Civils de LyonOTHER | 1 | Dec 27, 2021 | clinicaltrials |
| NCT04282070 | SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 | 91 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05162872 | Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 99 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT02178345 | Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer | completed | — | 123 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05124938 | Assessment of CA 19-9 in Patients' With Thyroid Malignancies | unknown | — | 120 | Sohag UniversityOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT05126160 | Immune Score Based Radiomics in Nasopharyngeal Carcinoma | recruiting | — | 494 | Zhejiang Cancer HospitalOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT05112510 | Prognostic Prediction of NPC Based on MR Diffusion-weighted Imaging | unknown | — | 125 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT02642107 | Individualized Elective Neck Irradiation Based on MRI in NPC Patients(NPC-CTVn) | completed | Phase 3 | 446 | Sun Yat-sen UniversityOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT00592501 | Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Massachusetts General HospitalOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03096808 | Adaptive Radiotherapy for Head and Neck Cancer | completed | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT05092217 | Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 80 | Eye & ENT Hospital of Fudan UniversityOTHER | 0 | Oct 25, 2021 | clinicaltrials |
| NCT03352778 | IMRT vs 2DRT for NPC Patients | completed | — | 60 | Chinese University of Hong KongOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT02041260 | A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting | unknown | Phase 2 | 43 | Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT02289807 | Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy | withdrawn | N/A | 0 | Sun Yat-sen UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03139747 | UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone | suspended | Phase 2 | 5 | Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | withdrawn | Phase 2 | 0 | Antonio FojoOTHER | 0 | Oct 13, 2021 | clinicaltrials |
| NCT02764554 | Post-Marketing Surveillance of Lenvima in Korean Patients | completed | — | 132 | Eisai Korea Inc.INDUSTRY | 1 | Oct 7, 2021 | clinicaltrials |
| NCT01816984 | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04189003 | Molecular Signatures of HPV+ ORL Cancers (OROPAP)(OROPAP) | completed | — | 66 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT05052359 | Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours | completed | — | 37 | National University Health System, SingaporeOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT05062005 | ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 447 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT05054634 | Psycho-oncological Intervention Through Counselling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine(COUNTHY) | completed | — | 75 | QuironsaludOTHER | 1 | Sep 23, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Feb 25, 2022source: clinicaltrials